MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP trimmed its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 18.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 717,288 shares of the biopharmaceutical company's stock after selling 165,372 shares during the period. Dimensional Fund Advisors LP owned approximately 1.14% of MacroGenics worth $2,331,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. American Century Companies Inc. purchased a new stake in MacroGenics in the 4th quarter worth $38,000. Sanders Morris Harris LLC bought a new position in MacroGenics during the 4th quarter valued at about $40,000. Jump Financial LLC bought a new position in MacroGenics in the 4th quarter worth about $44,000. XML Financial LLC grew its stake in MacroGenics by 31.6% in the 4th quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company's stock worth $75,000 after acquiring an additional 5,569 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of MacroGenics by 45.4% during the fourth quarter. Wells Fargo & Company MN now owns 29,838 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 9,312 shares in the last quarter. 96.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MGNX. Barclays reiterated an "overweight" rating and set a $3.00 price objective (down from $8.00) on shares of MacroGenics in a research note on Wednesday, May 14th. HC Wainwright decreased their target price on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, March 25th. Stifel Nicolaus cut their price objective on shares of MacroGenics from $6.00 to $5.00 and set a "hold" rating for the company in a report on Wednesday, May 14th. Finally, StockNews.com cut shares of MacroGenics from a "buy" rating to a "hold" rating in a report on Friday, March 21st. Eight research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $6.38.

MacroGenics Stock Performance

Shares of MGNX stock traded down $0.03 on Tuesday, reaching $1.57. 26,445 shares of the company were exchanged, compared to its average volume of 827,233. MacroGenics, Inc. has a 1 year low of $0.99 and a 1 year high of $5.77. The company has a market cap of $98.74 million, a price-to-earnings ratio of -0.99 and a beta of 2.20. The business has a 50-day moving average price of $1.54 and a 200 day moving average price of $2.58.

MacroGenics (NASDAQ:MGNX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.04). MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%. The business had revenue of $13.19 million for the quarter, compared to analysts' expectations of $9.59 million. As a group, equities analysts anticipate that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.